The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview

Journal of Psychopharmacology
E Gouzoulis-Mayfrank, J Daumann

Abstract

The popular dance drug ecstasy (3,4-methylenedioxymethamphetamine -- MDMA) is neurotoxic upon central serotonergic neurons in laboratory animals and possibly also in humans. In recent years, several studies reported alterations of serotonergic transmission and neuropsychiatric abnormalities in ecstasy users which might be related to MDMA-induced neurotoxic brain damage. To date, the most consistent findings associate subtle cognitive, particularly memory, deficits with heavy ecstasy use. However, most studies have important inherent methodological problems. One of the most serious confounds is the widespread pattern of polydrug use which makes it dif.cult to relate the findings in user populations to one specific drug. The present paper represents a brief overview on this issue. The most commonly co-used substances are alcohol, cannabis and stimulants (amphetamines and cocaine). Stimulants are also neurotoxic upon both serotonergic and dopaminergic neurons. Hence, they may act synergistically with MDMA and enhance its long-term adverse effects. The interactions between MDMA and cannabis use may be more complex: cannabis use is a well-recognized risk factor for neuropsychiatric disorders and it was shown to contribute to psychol...Continue Reading

References

Jul 8, 1998·Proceedings of the National Academy of Sciences of the United States of America·A J HampsonD Wink
Aug 27, 1998·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·M J Morgan
Sep 19, 1998·European Addiction Research·P SchusterH U Wittchen
Dec 17, 1998·Neurology·K I BollaG A Ricaurte
Feb 23, 2000·Neuroreport·A GammaF X Vollenweider
May 16, 2000·Journal of Neurology, Neurosurgery, and Psychiatry·E Gouzoulis-MayfrankH Sass
May 24, 2000·Drug and Alcohol Dependence·A C ParrottJ J Turner
Jun 1, 2000·British Journal of Psychology·M WareingP N Murphy
Jul 7, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·T J OrnsteinT W Robbins
Aug 25, 2000·Psychopharmacology·J Rodgers
Sep 23, 2000·The American Journal on Addictions·S L SimonW Ling
Mar 7, 2001·The American Journal of Psychiatry·N D VolkowE N Miller
Mar 7, 2001·The American Journal of Psychiatry·N D VolkowJ Logan
Mar 29, 2001·Psychopharmacology·R J CroftJ G Gruzelier
May 1, 2001·The European Journal of Neuroscience·A J Hampson, M Grimaldi
Nov 1, 2001·Archives of General Psychiatry·H G PopeD Yurgelun-Todd
Jan 30, 2002·Trends in Molecular Medicine·Raphael MechoulamEsther Shohami
Feb 8, 2002·Journal of Addictive Diseases·Sara L SimonWalter Ling
Feb 8, 2002·Molecular Neurobiology·R I GrundyM Beltramo
Mar 7, 2002·JAMA : the Journal of the American Medical Association·Nadia SolowijUNKNOWN Marijuana Treatment Project Research Group
Oct 31, 2002·Human Psychopharmacology·Joerg DaumannEuphrosyne Gouzoulis-Mayfrank
Nov 14, 2002·Molecular Neurobiology·Mario van der SteltJohannes F G Vliegenthart
Nov 26, 2002·BMJ : British Medical Journal·George C PattonWayne Hall
Dec 11, 2002·Addiction·Neil G Simon, Richard P Mattick
Dec 31, 2002·Psychology of Addictive Behaviors : Journal of the Society of Psychologists in Addictive Behaviors·Kara S RiehmanM Douglas Anglin
Mar 27, 2003·Alcoholism, Clinical and Experimental Research·Andrea Lawton-CraddockRick Tivis
Jul 19, 2003·Pharmacological Reviews·A Richard GreenM Isabel Colado
Aug 19, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Euphrosyne Gouzoulis-MayfrankJoerg Daumann
Sep 5, 2003·Psychopharmacology·Richard Ian DaftersAnnie Claire Talbot
Oct 17, 2003·Neuroreport·Jörg DaumannEuphrosyne Gouzoulis-Mayfrank
Nov 18, 2003·Addiction·Louisa DegenhardtMichael Lynskey
Dec 4, 2003·Psychopharmacology·Jonathan P Roiser, Barbara J Sahakian
Feb 3, 2004·The American Journal of Psychiatry·Gene-Jack WangJoanna S Fowler

❮ Previous
Next ❯

Citations

Mar 7, 2012·Archives of Toxicology·Márcia CarvalhoMaria de Lourdes Bastos
Mar 28, 2007·Psychopharmacology·Clara TouriñoOlga Valverde
Nov 9, 2007·Psychological Medicine·T SchiltW van den Brink
Feb 21, 2009·Eye·A Tandon, A Mulvihill
Dec 19, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Johannes G RamaekersElia Formisano
Dec 17, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Yen F TaiPaola Piccini
Apr 27, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Gerry JagerNick F Ramsey
Apr 20, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Matthew L BanksMichael A Nader
Oct 10, 2008·Brain : a Journal of Neurology·Maartje M L de WinWim van den Brink
Aug 30, 2008·Srpski arhiv za celokupno lekarstvo·Zorana Pavlović, Branko Jakovljević
Jan 21, 2014·Psychopharmacology·Claire WhiteMark Edwards
Oct 14, 2009·Psychopharmacology·Thelma SchiltBen Schmand
Aug 9, 2007·Psychopharmacology·Patricia RobledoRafael Maldonado
Oct 2, 2008·The British Journal of Psychiatry : the Journal of Mental Science·Maartje M L de WinWim van den Brink
May 1, 2009·Substance Use & Misuse·Z H WuL Cottler
Dec 17, 2009·Substance Use & Misuse·Stella Pereira de AlmeidaMaria Teresa Araujo Silva
May 15, 2007·The American Journal of Drug and Alcohol Abuse·J F GoldingZ Denton
Dec 28, 2010·Neuroscience and Biobehavioral Reviews·Susan Schenk
Jan 27, 2009·The International Journal on Drug Policy·Rachael Green, David Moore
Oct 14, 2008·Toxicology·Helena PontesMaria Lourdes Bastos
Sep 27, 2007·Human Psychopharmacology·Konstantine K ZakzanisDiana Jovanovski
Nov 11, 2008·Annals of the New York Academy of Sciences·Jerrold S MeyerValerie E Vancollie
Dec 25, 2010·Addiction·John E FiskFlorentia Hadjiefthyvoulou
Sep 29, 2011·Human Psychopharmacology·Rowan P OgeilJillian H Broadbear
Mar 6, 2012·Human Psychopharmacology·Elizabeth MurrayJohn Brown
Jul 27, 2010·The American Journal on Addictions·Michelle R Resor, Theodore V Cooper
Mar 6, 2010·Annals of the New York Academy of Sciences·Stephanie C Licata, Perry F Renshaw

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.